<?xml version="1.0" encoding="UTF-8"?>
<p>One such substance is polyI:C, a TLR3 agonist shown to induce differentiation of mDC, promote Th1 activation with IL-12 and type I IFN production, the activation of the innate immune response and reversing the PGD2 effects in the lungs (
 <xref rid="b72-ijmm-46-02-0489" ref-type="bibr">72</xref>,
 <xref rid="b73-ijmm-46-02-0489" ref-type="bibr">73</xref>). A shortcoming of the polyI:C may be its requirement for either RIG-1 or MDA5 activity, which are known to be inactivated by coronaviruses and render polyI:C ineffective post-infection, limiting it to a prevention drug (
 <xref rid="b74-ijmm-46-02-0489" ref-type="bibr">74</xref>).
</p>
